CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To identify effective novel agents against CML-LSCs, the authors performed a comprehensive 82-agent ex vivo drug screen on patient-derived CD34+ cells—a compartment enriched for CML-LSCs.